Clinical trial
Combidex USPIO - Ultra-small Superparamagnetic Iron Oxide
NCT00188695 · University Health Network, Toronto, Other · Completed
Key facts
| NCT number | NCT00188695 |
|---|---|
| Title | Combidex USPIO - Ultra-small Superparamagnetic Iron Oxide |
| Official title | A Pilot Study of MR Imaging With Ultra-small Superparamagnetic Iron Oxide for Pelvic Lymph Node Target Definition |
| Lead sponsor | University Health Network, Toronto, Other |
| Collaborators | Princess Margaret Hospital, Canada |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Uterine Neoplasms, Cervix Neoplasms, Bladder Neoplasms, Prostatic Neoplasms |
| Intervention type | Procedure |
| Interventions | MRI contrast agent Combidex (ferumoxtran-10) |
| Enrollment | 61 |
| Start date | Apr 1, 2004 |
| Primary completion | Jun 1, 2006 |
| Completion | Mar 15, 2022 |
| First posted | Sep 16, 2005 |
| Last update posted | Oct 7, 2022 |
| Countries | Canada |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: